What's Going On With Cardiff Oncology Stock On Tuesday?
What's Going On With Cardiff Oncology Stock On Tuesday?
Efficacy and safety data are for all evaluable patients as of November 26.On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).
在週二，Cardiff Oncology，Inc.（納斯達克：CRDF）公佈了CRDF-004第二階段試驗的初步數據，該試驗評估了onvansertib與標準治療（SoC）聯合使用在一線RAS突變轉移性結直腸癌（mCRC）患者中的效果。
The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation.
CRDF-004 II 期試驗目前正在招募有記錄的 KRAS 或 NRAS 突變的 mCRC 患者。
Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:1 ratio to either 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone.
onvansertib 加入了由 FOLFIRI 加上貝伐單抗或 FOLFOX 加上貝伐單抗組成的 SoC。患者被隨機分配到 20mg 的 onvansertib 加 SoC、30mg 的 onvansertib 加 SoC 或僅 SoC 的比例爲 1:1:1。
Efficacy and safety data are for all evaluable patients as of November 26.
截至 11 月 26 日的有效患者的療效和安全性數據。
An objective response rate of 57% was observed in all onvansertib patients, with 50% in the 20mg dose of onvansertib + SoC arm and 64% in the 30mg dose of onvansertib + SoC arm, compared to 33% in the SoC alone arm.
在所有接受 onvansertib 的患者中觀察到 57% 的客觀反應率，其中 20mg onvansertib + SoC 組爲 50%，30mg onvansertib + SoC 組爲 64%，而僅 SoC 組爲 33%。
Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib combined with the SoC compared to the control arms and 20mg dose of onvansertib arms.
蜘蛛圖顯示了每個患者腫瘤大小從基線到現在的變化，表明接受 30mg onvansertib 聯合 SoC 的患者比對照組和 20mg onvansertib 組觀察到了更深入的反應。
Onvansertib, in combination with chemo/bevacizumab, was well-tolerated, and no major or unexpected toxicities were observed.
onvansertib 與化療/貝伐單抗聯合使用耐受良好，沒有觀察到嚴重或意外的毒性。
Additional clinical data from the CRDF-004 trial is expected in 1H 2025.
預計將於 2025 年上半年獲得來自 CRDF-004 試驗的額外臨床數據。
"We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology.
"我們對於在隨機第一階段RAS突變mCRC CRDF-004試驗中觀察到的onvansertib與標準療法結合的強有效性信號和良好安全性特徵感到非常鼓舞，"Cardiff Oncology首席醫療官Fairooz Kabbinavar博士說。
"Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses."
"我們的數據顯示，在接受30毫克onvansertib與標準療法結合的患者中，客觀反應率爲64%，顯著高於僅接受標準療法的對照組觀察到的33%的客觀反應率。此外，正如在蜘蛛圖中所見，我們觀察到接受30毫克onvansertib的患者腫瘤反應更深，與接受20毫克劑量的患者相比，兩者的安全性特徵相似。"
Price Action: CRDF stock was trading 52% higher to $3.71 at the last check on Tuesday.
價格動態：在週二的最後檢查中，CRDF股票交易價格上漲52%至3.71美元。
- Rocket Lab Achieves Milestone In Hypersonic Testing for DoD's MACH-TB Project
- 火箭實驗室在國防部的MACH-Tb項目的超音速測試中達成了里程碑。
